From Hereditary Risk to Residual Disease: Natera’s Integrated Vision for Precision Oncology with Adam ElNaggar, MD
Adam ElNaggar, MD of Natera, discusses the rise of MRD testing and ctDNA monitoring in oncology, highlighting Natera's Signatera and Latitude tests. The conversation covers hereditary cancer testing and the future of personalized medicine where ctDNA status influences staging.